Jounce Therapeutics Inc (NASDAQ:JNCE) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $29.00 for the company and are predicting that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also assigned Jounce Therapeutics an industry rank of 181 out of 265 based on the ratings given to related companies.
Several brokerages have recently issued reports on JNCE. Zacks Investment Research upgraded Jounce Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. JPMorgan Chase & Co. set a $28.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, Robert W. Baird reiterated a “buy” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research report on Friday, November 10th.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million during the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. Jounce Therapeutics’s quarterly revenue was up 7.1% on a year-over-year basis. research analysts expect that Jounce Therapeutics will post -0.86 EPS for the current fiscal year.
In other Jounce Therapeutics news, Director Barbara Gayle Duncan sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $25.00, for a total value of $100,000.00. Following the completion of the sale, the director now directly owns 4,000 shares in the company, valued at $100,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teachers Advisors LLC lifted its position in Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares during the period. Alps Advisors Inc. lifted its position in Jounce Therapeutics by 12.5% in the fourth quarter. Alps Advisors Inc. now owns 35,642 shares of the company’s stock worth $454,000 after purchasing an additional 3,966 shares during the period. Strs Ohio lifted its position in Jounce Therapeutics by 10.7% in the third quarter. Strs Ohio now owns 41,300 shares of the company’s stock worth $643,000 after purchasing an additional 4,000 shares during the period. Bank of New York Mellon Corp lifted its position in Jounce Therapeutics by 10.8% in the fourth quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock worth $585,000 after purchasing an additional 4,467 shares during the period. Finally, American International Group Inc. lifted its position in Jounce Therapeutics by 132.2% in the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after purchasing an additional 5,442 shares during the period. Hedge funds and other institutional investors own 47.47% of the company’s stock.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.